Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Virax Biolabs Group's 3-Year RORE % for the quarter that ended in Mar. 2026 was -47.39%.
The industry rank for Virax Biolabs Group's 3-Year RORE % or its related term are showing as below:
VRAX's 3-Year RORE % is ranked worse than 80.33% of 1291
companies
in the Biotechnology industry
Industry Median: -11.44
vs VRAX: -47.39
Virax Biolabs Group (NAS:VRAX) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Virax Biolabs Group 3-Year RORE % Related Terms
Virax Biolabs Group 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRAX vs BBLG, PKTX, OGEN: 3-Year RORE % Comparison
For the Biotechnology subindustry, Virax Biolabs Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Virax Biolabs Group (VRAX) has a 3-Year RORE % of -47.39 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Virax Biolabs Group and its competitors. According to the industry distribution chart, Virax Biolabs Group ranks #1037 out of 1291 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Virax Biolabs Group's 3-Year RORE % too high?
Virax Biolabs Group's current 3-Year RORE % is -47.39. Based on the distribution chart, Virax Biolabs Group ranks #1037 out of 1291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's 3-Year RORE % compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #1037 out of 1291 companies for 3-Year RORE %. This places Virax Biolabs Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current 3-Year RORE % is -47.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.63, compared to a current price of $3.88 — trading 6.9% above its estimated fair value. The current 3-Year RORE % is -47.39. Virax Biolabs Group's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current 3-Year RORE % is -47.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.88 is trading 6.9% above its estimated GF Value™ of $3.63.
GuruFocus considers Virax Biolabs Group to be Fairly Valued.
Key valuation signals for VRAX:
3-Year RORE %: -47.39
GF Value™: $3.63 vs. price of $3.88 (6.9% above fair value)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
44GF Score
Get the complete analysis for VRAX
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
